Impact of Matrix Metalloproteinase-11 Gene Polymorphisms on Biochemical Recurrence and Clinicopathological Characteristics of Prostate Cancer

Chun-Yu Hsieh, Ying-Erh Chou, Chia-Yen Lin, Shian-Shiang Wang, Ming-Hsien Chien, Chih-Hsin Tang, Jian-Cheng Lin, Yu-Ching Wen and Shun-Fa Yang
Additional contact information
Chun-Yu Hsieh: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Ying-Erh Chou: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Chia-Yen Lin: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Shian-Shiang Wang: School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Ming-Hsien Chien: Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
Chih-Hsin Tang: Department of Pharmacology, School of Medicine, China Medical University, Taichung 404, Taiwan
Jian-Cheng Lin: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Yu-Ching Wen: Department of Urology, Wan Fang Hospital, Taipei Medical University, Taipei 110, Taiwan
Shun-Fa Yang: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan

IJERPH, 2020, vol. 17, issue 22, 1-12

Abstract: Prostate cancer is among the most common malignant tumors worldwide. Matrix metalloproteinase (MMP)-11 is involved in extracellular matrix degradation and remodeling and plays an essential role in cancer development and metastasis. This study investigated the association of MMP-11 polymorphisms with the clinicopathological characteristics and biochemical recurrence of prostate cancer. Five single-nucleotide polymorphisms (SNPs) of the MMP-11 were analyzed in 578 patients with prostate cancer through real-time polymerase chain reaction analysis. A prostate-specific antigen level of >10 ng/mL, Gleason grade groups 4 + 5, advanced tumor stage, lymph node metastasis, invasion, and high-risk D’Amico classification were significantly associated with biochemical recurrence in the patients ( p < 0.001). MMP-11 rs131451 “TC + CC” polymorphic variants were associated with advanced clinical stage (T stage; p = 0.007) and high-risk D’Amico classification ( p = 0.015) in patients with biochemical recurrence. These findings demonstrate that MMP-11 polymorphisms were not associated with prostate cancer susceptibility; however, the rs131451 polymorphic variant was associated with late-stage tumors and high-risk D’Amico classification in prostate cancer patients with biochemical recurrence. Thus, the MMP-11 SNP rs131451 may contribute to the tumor development in prostate cancer patients with biochemical recurrence.

Keywords: prostate cancer; MMP-11; polymorphism (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/22/8603/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/22/8603/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:22:p:8603-:d:447748

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().